XORTX Therapeutics Files October 2024 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Oct 18, 2024 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, 6-k, reporting-status
TL;DR
XORTX filed its monthly 6-K, confirming it's a 20-F filer. CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 18, 2024, to report its activities for the month of October 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides routine updates on the company's status as a foreign private issuer and its reporting obligations, which is standard for companies listed on US exchanges but based internationally.
Risk Assessment
Risk Level: low — This is a routine administrative filing (Form 6-K) confirming reporting status and signed by the CEO, with no new financial or operational information disclosed.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- October 18, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the issuer makes or is required to make public in its home country or to send or make public to its security holders.
Which annual report form does XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. files its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
The Form 6-K filing was signed by Allen Davidoff, Chief Executive Officer of XORTX Therapeutics Inc.
What is the filing date of this Form 6-K?
This Form 6-K was filed on October 18, 2024.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-18 17:17:51
Filing Documents
- f6k_101824.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-005701.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: October 18, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Press Release dated October 18, 2024